GB201904375D0 - Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders - Google Patents

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Info

Publication number
GB201904375D0
GB201904375D0 GBGB1904375.1A GB201904375A GB201904375D0 GB 201904375 D0 GB201904375 D0 GB 201904375D0 GB 201904375 A GB201904375 A GB 201904375A GB 201904375 D0 GB201904375 D0 GB 201904375D0
Authority
GB
United Kingdom
Prior art keywords
treatment
pharmaceutical compositions
novel compounds
inflammatory disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1904375.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Priority to GBGB1904375.1A priority Critical patent/GB201904375D0/en
Publication of GB201904375D0 publication Critical patent/GB201904375D0/en
Priority to PH1/2021/552377A priority patent/PH12021552377A1/en
Priority to US17/599,447 priority patent/US20220296573A1/en
Priority to BR112021019099A priority patent/BR112021019099A2/pt
Priority to SG11202110643YA priority patent/SG11202110643YA/en
Priority to PCT/EP2020/058061 priority patent/WO2020200898A1/en
Priority to KR1020217035256A priority patent/KR20210143905A/ko
Priority to AU2020252900A priority patent/AU2020252900A1/en
Priority to EP20714521.0A priority patent/EP3947374A1/en
Priority to CN202080026038.XA priority patent/CN113677678A/zh
Priority to MX2021011574A priority patent/MX2021011574A/es
Priority to JP2021557759A priority patent/JP2022526553A/ja
Priority to CA3134732A priority patent/CA3134732A1/en
Priority to IL286688A priority patent/IL286688A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1904375.1A 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders Ceased GB201904375D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1904375.1A GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CA3134732A CA3134732A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
KR1020217035256A KR20210143905A (ko) 2019-03-29 2020-03-24 염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
EP20714521.0A EP3947374A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
BR112021019099A BR112021019099A2 (pt) 2019-03-29 2020-03-24 Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
SG11202110643YA SG11202110643YA (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058061 WO2020200898A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PH1/2021/552377A PH12021552377A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2020252900A AU2020252900A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US17/599,447 US20220296573A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN202080026038.XA CN113677678A (zh) 2019-03-29 2020-03-24 用于治疗炎性障碍的新化合物及其药物组合物
MX2021011574A MX2021011574A (es) 2019-03-29 2020-03-24 Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
JP2021557759A JP2022526553A (ja) 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物
IL286688A IL286688A (en) 2019-03-29 2021-09-26 New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1904375.1A GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
GB201904375D0 true GB201904375D0 (en) 2019-05-15

Family

ID=66442789

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1904375.1A Ceased GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Country Status (14)

Country Link
US (1) US20220296573A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947374A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022526553A (cg-RX-API-DMAC7.html)
KR (1) KR20210143905A (cg-RX-API-DMAC7.html)
CN (1) CN113677678A (cg-RX-API-DMAC7.html)
AU (1) AU2020252900A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019099A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134732A1 (cg-RX-API-DMAC7.html)
GB (1) GB201904375D0 (cg-RX-API-DMAC7.html)
IL (1) IL286688A (cg-RX-API-DMAC7.html)
MX (1) MX2021011574A (cg-RX-API-DMAC7.html)
PH (1) PH12021552377A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110643YA (cg-RX-API-DMAC7.html)
WO (1) WO2020200898A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
WO2023075420A1 (ko) 2021-10-26 2023-05-04 주식회사 엘지에너지솔루션 전극 조립체의 제조방법
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
US7566781B2 (en) * 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
EP2688872A4 (en) * 2011-03-22 2014-08-27 Merck Sharp & Dohme AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
WO2014139882A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK1231480A1 (zh) * 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
EP3394066A2 (en) * 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
PH12021552377A1 (en) 2022-10-03
MX2021011574A (es) 2021-10-13
KR20210143905A (ko) 2021-11-29
US20220296573A1 (en) 2022-09-22
SG11202110643YA (en) 2021-10-28
EP3947374A1 (en) 2022-02-09
CN113677678A (zh) 2021-11-19
JP2022526553A (ja) 2022-05-25
WO2020200898A1 (en) 2020-10-08
AU2020252900A1 (en) 2021-11-25
BR112021019099A2 (pt) 2021-11-30
CA3134732A1 (en) 2020-10-08
IL286688A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL286677A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
IL286688A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201911868D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201610056D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
IL286685A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201610055D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
PL3724173T3 (pl) Związki do leczenia zaburzeń nerwowo-mięśniowych
IL287392A (en) New compounds and their pharmaceutical preparations for the treatment of kidney diseases
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK40068361A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK40068360A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK40068861A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB202001420D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB202001421D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201807222D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammation disorders
GB201905536D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of metabolic disorders
HK40083625A (en) Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)